Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861879 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| SCHEMBL6983314 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| SCHEMBL5720954 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| Hydrochloric Acid SCHEMBL7594743 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| Hydrochloric Acid SCHEMBL6773954 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| Hydrochloric Acid SCHEMBL7589162 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| SCHEMBL20545260 | 0.91 | CTSA (0.56) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| SCHEMBL20545257 | 0.91 | CTSA (0.56) | KMT2ASMN1; SMN2MEN1ANPEPENPEP | |
| SCHEMBL20546108 | 0.88 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1CTSAFFAR1 | |
| SCHEMBL30644987 | 0.88 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1CTSAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2834220-B1 | 4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9409892-B2 | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| CN-105377851-A | BET bromodomain inhibitors and therapeutic methods using these inhibitors | UNIV MICHIGAN REGENTS | 2016-03-02 | — | — | CN | disclosed |
| WO-2002074730-A1 | INHIBITORS OF INTEGRIN αvβ¿6? | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
| US-6451789-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | LES LABORTOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | disclosed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| CN-1277194-A | New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them | ADIR (FR) | 2000-12-20 | — | — | CN | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | SULT2A1, GRIN2A, NR3C1 | KMT2A 554/4885SMN1; SMN2 682/4885MEN1 4318/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | KMT2A 2421/4885SMN1; SMN2 3428/4885MEN1 1437/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | KMT2A 337/4885SMN1; SMN2 3270/4885MEN1 3205/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | KMT2A 337/4885SMN1; SMN2 3270/4885MEN1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.